当前位置:首页>产品中心>单抗/多抗>HEK293T SARS-CoV-2 Spike (PP) Stable Cell Line|HEK293T SARS-CoV-2刺突(PP)稳定细胞系(靶标:新冠病毒刺突蛋白(PP突变)稳定表达细胞系)

HEK293T SARS-CoV-2 Spike (PP) Stable Cell Line|HEK293T SARS-CoV-2刺突(PP)稳定细胞系(靶标:新冠病毒刺突蛋白(PP突变)稳定表达细胞系)

  • 货号:RB9TVK474818
  • 价格:面议
  • 点击:388

产品介绍

产品参数

宿主种属HEK293T
应用FCM
靶标SARS-CoV-2 Spike (PP)
稳定性和储存Frozen in liquid nitrogen.
登录号P0DTC2
背景信息

Spike glycoprotein (SARS-CoV-2 Spike (PP)) is a ~141 kDa protein. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2. When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane. When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane. Alternatively, may use NRP1/NRP2 and integrin as entry receptors.

1. Hoffmann, M. et al. (2020) Cell 181, 271-280.e8. PMID: 32142651
2. Walls, AC. et al. (2020) Cell 181, 281-292.e6. PMID: 32155444
3. Cao, W. et al. (2021) Biophysical journal 120, 1011-1019. PMID: 33607086
4. Takeda, M. (2022) Microbiology and immunology 66, 15-23. PMID: 34561887
5. Wrapp, D. et al. (2020) Science (New York, N.Y.) 367, 1260-1263. PMID: 32075877
6. Ou, X. et al. (2020) Nature communications 11, 1620. PMID: 32221306
7. Wang, J. et al. (2021) Cell discovery 7, 119. PMID: 34903715
8. Wang, X. et al. (2023) Journal of virology 97, e0161122. PMID: 36779763
9. Daly, JL. et al. (2020) Science (New York, N.Y.) 370, 861-865. PMID: 33082294
10. Cantuti-Castelvetri, L. et al. (2020) Science (New York, N.Y.) 370, 856-860. PMID: 33082293
产品特性Growth Properties: Adherent; Selection Marker: Puromycin (1 μg/mL)
种属Viral (SARS-CoV-2)
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 483
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 606
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 428
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 576
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 438
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 525
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 275
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 340
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 312
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 522
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 636
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 444
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 413
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 627
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 649
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 482
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 332
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 633
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 507
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 317
总计 33037 个记录,共 1652 页,当前第 1650 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00